title: Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation.
abstract: Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection. Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy. We believe that immunosuppression-induced pneumonitis in a lung allograft is a serious dilemma for lung transplant physicians
authors.affiliation: Department of Respiratory Medicine, The Alfred Hospital, Melbourne, Australia.
authors.forename: Tanya J
authors.initials: TJ
authors.lastname: McWilliams
authors.forename: Bronwyn J
authors.initials: BJ
authors.lastname: Levvey
authors.forename: Prudence A
authors.initials: PA
authors.lastname: Russell
authors.forename: David G
authors.initials: DG
authors.lastname: Milne
authors.forename: Greg I
authors.initials: GI
authors.lastname: Snell
mesh_terms: D000328:Adult; D016041:Heart-Lung Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007674:Kidney Diseases / Q000188:drug therapy; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D016040:Lung Transplantation; D008297:Male; D020123:Sirolimus / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus